Omeros (OMER) Capital Leases (2017 - 2018)
Omeros (OMER) reported Capital Leases of $1.6 million for Q4 2018, up 94.81% on a YoY basis from $810000.0 in Q4 2017, and up 94.81% sequentially from $810000.0 in Q4 2017.
Omeros (OMER) Capital Leases (2017 - 2018) Analysis & Trends
Omeros (OMER) has 2 years of Capital Leases data on file, last reported at $1.6 million in Q4 2018.
- For the quarter ending Q4 2018, Capital Leases rose 94.81% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2018 stood at $1.6 million (up 94.81% YoY), and the FY2018 full-year result was $1.6 million, up 94.81% from the prior year.
- Capital Leases advanced to $1.6 million in Q4 2018, from $810000.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $1.6 million in Q4 2018 to a low of $810000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.58 Mn |
| Dec 31, 2017 | 810,000.00 |